Zhangzhou Pientzehuang Pharmaceutical Co Ltd banner

Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436

Watchlist Manager
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Logo
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Watchlist
Price: 144.11 CNY -0.67%
Market Cap: ¥86.9B

EV/EBITDA

34.9
Current
13%
Cheaper
vs 3-y average of 40.4

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
34.9
=
Enterprise Value
¥100.1B
/
EBITDA
¥2.5B

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
34.9
=
Enterprise Value
¥100.1B
/
EBITDA
¥2.5B

Valuation Scenarios

Zhangzhou Pientzehuang Pharmaceutical Co Ltd is trading below its 3-year average

If EV/EBITDA returns to its 3-Year Average (40.4), the stock would be worth ¥166.57 (16% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-32%
Maximum Upside
+50%
Average Upside
4%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 34.9 ¥144.11
0%
3-Year Average 40.4 ¥166.57
+16%
5-Year Average 52.3 ¥215.61
+50%
Industry Average 23.9 ¥98.61
-32%
Country Average 28.8 ¥118.9
-17%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
¥100.1B
/
Oct 2025
¥2.5B
=
34.9
Current
¥100.1B
/
Dec 2025
¥3.5B
=
28.8
Forward
¥100.1B
/
Dec 2026
¥3.9B
=
25.7
Forward
¥100.1B
/
Dec 2027
¥4.6B
=
21.6
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
CN
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
86.9B CNY 34.9 35.9
US
Eli Lilly and Co
NYSE:LLY
853.2B USD 28 41.3
US
Johnson & Johnson
NYSE:JNJ
544.6B USD 16.6 25.9
CH
Roche Holding AG
SIX:ROG
248.4B CHF 11.7 19.8
UK
AstraZeneca PLC
LSE:AZN
225.8B GBP 16.2 29.2
CH
Novartis AG
SIX:NOVN
226.8B CHF 12.4 20
US
Merck & Co Inc
NYSE:MRK
278.5B USD 9.5 15.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD 386.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 7.9 10.7
US
Pfizer Inc
NYSE:PFE
155.3B USD 7.7 20
US
Bristol-Myers Squibb Co
NYSE:BMY
119.6B USD 7.2 17

Market Distribution

In line with most companies in China
Percentile
56th
Based on 5 409 companies
56th percentile
34.9
Low
0 — 16.3
Typical Range
16.3 — 53.1
High
53.1 —
Distribution Statistics
China
Min 0
30th Percentile 16.3
Median 28.8
70th Percentile 53.1
Max 49 021

Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Glance View

Market Cap
86.9B CNY
Industry
Pharmaceuticals

Zhangzhou Pientzehuang Pharmaceutical Co. Ltd., nestled in the heart of Fujian Province, China, is a firm steeped in history and tradition, yet thriving in today’s modern pharmaceutical landscape. The company is best known for its signature product, Pientzehuang Pills, a centuries-old traditional Chinese medicine believed to offer hepatoprotective and detoxifying properties. Rooted in ancient formulations, Pientzehuang Pills are celebrated for their efficacy in addressing liver ailments and enhancing overall vitality. This has secured their place as a staple in Chinese households, maintaining cultural resonance while appealing to a broader audience through the global rise in demand for alternative medicine. The firm operates with a delicate balance, integrating traditional Chinese medicine practices with increasingly sophisticated production technologies to ensure quality consistency and scalability. Zhangzhou Pientzehuang leverages its brand heritage and expertise in traditional herbal remedies to drive revenue. The company has adeptly positioned itself within both domestic and international markets, capitalizing on the growing interest in holistic health approaches. By focusing on research and development, the company continues to innovate, expanding its product line to include health supplements and preventive solutions that cater to modern health challenges. Its strategic distribution channels, including hospitals, pharmacies, and online platforms, enable broad market penetration, ensuring robust sales growth. This dual strategy of preserving the traditional while embracing the modern allows the company to keep its legacy relevant in a competitive pharmaceutical industry, thereby securing its stronghold in the market and ensuring sustained financial performance.

Intrinsic Value
87.85 CNY
Overvaluation 39%
Intrinsic Value
Price ¥144.11
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett